Bone Marrow Transplantation and Medical Tourism at Erciyes University - A Single Center Experience

Document Type : Review Article


1 Department of Hematology, Faculty of Medicine, Erciyes University, Kayseri, Turkey

2 Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erciyes University, Kayseri, Turkey


Medical tourism emerged when people were challenged with high costs and slow service in medical care. As a consequence of these issues, people started to look for medical treatment in other countries. Globalization accelerated the growth of medical tourism. Several “push” and “pull” factors play roles in the motivation of patients to become a medical tourist. This review addresses the different aspects of medical tourism in general, describes the development of medical tourism in Turkey, and describes experiences with medical tourism in the Bone Marrow Transplantation Center (BMTC) at Erciyes University, Kayseri, Turkey. Since January 2016, an international collaboration has existed between BMTC and the King Hamed University Hospital (KHUH) in Bahrain. Ten allogeneic stem cell transplantations (SCTs) have been performed on patients from Bahrain with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma, and myelofibrosis. Furthermore, ten autologous SCT have been conducted on patients from Bahrain with multiple myeloma (MM), Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL). In 2016, transplant-related mortality (TRM) at 100 days among Bahrain patients was 0% compared to 2.6% in all patients. Although these numbers are small, the first results show that the outcomes of international patients are similar to those of non-international patients. In our experience, the key to a successful collaboration between international hospitals is having close communication regarding the treatment of the international patient. The outcome of a large group of international compared with non-international patients should be further studied.


  1. Ramirez de Arellano AB. Patients without borders: the emergence of medical tourism. Int J Health Serv. 2007;37(1):193-198. doi:10.2190/4857-468G-2325-47UU.
  2. Carrera P, Lunt N. A European perspective on medical tourism: the need for a knowledge base. Int J Health Serv. 2010;40(3):469-484. doi:10.2190/HS.40.3.e.
  3. Hanefeld J, Smith R, Horsfall D, Lunt N. What do we know about medical tourism? A review of the literature with discussion of its implications for the UK National Health Service as an example of a public health care system. J Travel Med. 2014;21(6):410-417. doi:10.1111/jtm.12147.
  4. Lunt N, Carrera P. Medical tourism: assessing the evidence on treatment abroad. Maturitas. 2010;66(1):27-32. doi:10.1016/j.maturitas.2010.01.017.
  5. Amouzagar S, Mojaradi Z, Izanloo A, Beikzadeh S, Milani M. Qualitative Examination of Health Tourism and Its Challenges. Int J Travel Med Glob Health. 2016;4(3):88-91. doi:10.21859/IJTMGH-040304.
  6. Crooks VA, Kingsbury P, Snyder J, Johnston R. What is known about the patient’s experience of medical tourism? A scoping review. BMC Health Serv Res. 2010;10:266. doi:10.1186/1472-6963-10-266.
  7. Masoud F, Alireza J, Mahmoud K, Zahra A. A systematic review of publications studies on medical tourism. J Educ Health Promot. 2013;2:51. doi:10.4103/2277-9531.119037.
  8. Jabbari A, Delgoshaei B, Mardani R, Tabibi SJ. Medical tourism in Iran: Issues and challenges. J Educ Health Promot. 2012;1:39. doi:10.4103/2277-9531.104809.
  9. Mogaka JJ, Tsoka-Gwegweni JM, Mupara LM, Mashamba- Thompson T. Role, structure and effects of medical tourism in Africa: a systematic scoping review protocol. BMJ Open. 2017;7(6):e013021. doi:10.1136/bmjopen-2016-013021.
  10. Morciano C, Laricchiuta P, Taruscio D, Schunemann H. European Reference Networks and Guideline Development and Use: Challenges and Opportunities. Public Health Genomics. 2015;18(5):318-320. doi:10.1159/000435852.
  11. Rokni L, Avci T, Park SH. Barriers of Developing Medical Tourism in a Destination: A Case of South Korea. Iran J Public Health. 2017;46(7):930-937.
  12. Johnston R, Crooks VA, Snyder J, Kingsbury P. What is known about the effects of medical tourism in destination and departure countries? A scoping review. Int J Equity Health. 2010;9:24. doi:10.1186/1475-9276-9-24.
  13. Hanefeld J, Horsfall D, Lunt N, Smith R. Medical tourism: a cost or benefit to the NHS? PLoS One. 2013;8(10):e70406. doi:10.1371/journal.pone.0070406.
  14. Crooks VA, Ormond M, Jin KN. Reflections on ‘medical tourism’ from the 2016 Global Healthcare Policy and Management Forum. BMC Proc. 2017;11(Suppl 8):6. doi:10.1186/s12919-017-0075-8.
  15. De Neve JW, Dave R, Gurel M, Subramanian SV. International patients in a Turkish hospital: a quantitative study on cross-border health care at the intersection of Eastern Europe, Asia and the Middle East. World Hosp Health Serv. 2012;48(1):5-7.
  16. Ucak H. The relationship between the growth in the health sector and inbound health tourism: the case of Turkey. Springerplus. 2016;5(1):1685. doi:10.1186/s40064-016-3341-8.
  17. Ozan-Rafferty ME, Johnson JA, Shah GH, Kursun A. In the words of the medical tourist: an analysis of Internet narratives by health travelers to Turkey. J Med Internet Res. 2014;16(2):e43. doi:10.2196/jmir.2694.
  18. Woodhead A. Scoping medical tourism and international hospital accreditation growth. Int J Health Care Qual Assur. 2013;26(8):688- 702. doi:10.1108/IJHCQA-10-2011-0060.
  19. Republic of Turkey, Ministry of Health, Directorate general of Health Services, Department of health tourism. Evaluation Report on Medical Tourism in Turkey. Ankara: Ministry of Health; 2013;
  20. Fetscherin M, Stephano RM. The medical tourism index: Scale development and validation. Tour Manag. 2016;52:539-556. doi:10.1016/j.tourman.2015.08.010.
  21. Lunt N, Horsefall D, Hanefeld J. Handbook on Medical Tourism and Patient Mobility. Northampton, MA: Edward Elgar Publishing Ltd; 2015. doi:10.4337/9781783471195.
  22. Bortin MM. A compendium of reported human bone marrow transplants. Transplantation. 1970;9(6):571-587. doi:10.1097/00007890-197006000-00006.
  23. Thomas E, Storb R, Clift RA, et al. Bone-marrow transplantation (first of two parts). N Engl J Med. 1975;292(16):832-843. doi:10.1056/NEJM197504172921605.
  24. Arat M, Arpaci F, Ertem M, Gurman G. Turkish Transplant Registry: a comparative analysis of national activity with the EBMT European Activity Survey. Bone Marrow Transplant. 2008;42 Suppl 1:S142-s145. doi:10.1038/bmt.2008.144.
  25. Passweg JR, Baldomero H, Bader P, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017;52(6):811-817. doi:10.1038/bmt.2017.34.
  26. Sirinoglu Demiriz I, Tekgunduz E, Altuntas F. What is the most appropriate source for hematopoietic stem cell transplantation? Peripheral stem cell/bone marrow/cord blood. Bone Marrow Res. 2012;2012:834040. doi:10.1155/2012/834040.
  27. Armitage JO. The History of Autologous Hematopoietic Cell Transplantation. In: Thomas’ Hematopoietic Cell Transplantation.Oxford, UK: Wiley-Blackwell; 2009:8-14. doi:10.1002/9781444303537.ch2.
  28. Little MT, Storb R. History of haematopoietic stem-cell transplantation. Nat Rev Cancer. 2002;2(3):231-238. doi:10.1038/nrc748.
  29. Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124(3):344-353. doi:10.1182/blood-2014-02-514778.
  30. Mohty M, Harousseau JL. Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers. Haematologica. 2014;99(3):408-416. doi:10.3324/haematol.2013.096149.
  31. Robinson SP, Boumendil A, Finel H, et al. Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party. Bone Marrow Transplant. 2016;51(3):365-371. doi:10.1038/bmt.2015.286.
  32. Staton AD, Langston AA. Autologous stem cell transplant: still the standard for fit patients with mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2017;17s:S96-s99. doi:10.1016/j.clml.2017.02.021.
  33. Myers RM, Hill BT, Shaw BE, et al. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. Cancer. 2017. doi:10.1002/cncr.31114.
  34. Mancardi G, Sormani MP, Muraro PA, Boffa G, Saccardi R. Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis. Mult Scler. 2017:1352458517742532. doi:10.1177/1352458517742532.
  35. Mancardi GL, Sormani MP, Gualandi F, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology. 2015;84(10):981-988. doi:10.1212/WNL.0000000000001329.
  36. Schmoll HJ, Kollmannsberger C, Metzner B, et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol. 2003;21(22):4083-4091. doi:10.1200/JCO.2003.09.035.
  37. Nieto Y, Champlin RE, Wingard JR, et al. Status of high-dose chemotherapy for breast cancer: a review. Biol Blood Marrow Transplant. 2000;6(5):476-495. Doi:10.1016/S1083-8791(00)70019-X.
  38. Ades L, Mary JY, Robin M, et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood. 2004;103(7):2490-2497. doi:10.1182/blood-2003-07-2546.
  39. Kassim AA, Sharma D. Hematopoietic stem cell transplantation for sickle cell disease: The changing landscape. Hematol Oncol Stem Cell Ther. 2017;10(4):259-266. doi:10.1016/j.hemonc.2017.05.008.
  40. Tekgunduz E, Kaynar L, Goker H, et al. Retrospective analysis of adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation: A multicenter experience of daily practice. Transfus Apher Sci. 2016;54(1):41- 47. doi:10.1016/j.transci.2016.01.010.
  41. Eroglu C, Pala C, Kaynar L, et al. Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant. Leuk Lymphoma. 2013;54(11):2474-2479. doi:10.3109/10428194.2013.779691.
  42. Kaynar L, Demir K, Turak EE, et al. TcRalphabeta-depleted haploidentical transplantation results in adult acute leukemia patients. Hematology. 2017;22(3):136-144. doi:10.1080/102453 32.2016.1238182.
  43. Niederwieser D, Baldomero H, Szer J, et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant. 2016;51(6):778-785. doi:10.1038/bmt.2016.18.
  44. Metan G, Kaynar L, Yozgat N, et al. A change for the antibacterial treatment policy to decrease carbapenem consumption at a haematopoietic stem cell transplantation centre. Infez Med. 2017;25(1):33-37.
  45. Demiraslan H, Cevahir F, Berk E, Metan G, Cetin M, Alp E. Is surveillance for colonization of carbapenem-resistant gram-negative bacteria important in adult bone marrow transplantation units? Am J Infect Control. 2017;45(7):735-739. doi:10.1016/j.ajic.2017.01.006.
  46. Snowden JA, McGrath E, Duarte RF, et al. JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement. Bone Marrow Transplant. 2017;52(10):1367-1371. doi:10.1038/bmt.2017.54.
  47. Ali PA, Johnson S. Speaking my patient’s language: bilingual nurses’ perspective about provision of language concordant care to patients with limited English proficiency. J Adv Nurs. 2017;73(2):421-432. doi:10.1111/jan.13143.
  48. Flores G. The impact of medical interpreter services on the quality of health care: a systematic review. Med Care Res Rev. 2005;62(3):255-299. doi:10.1177/1077558705275416.
  49. Easley TJ. Medical Journals, Publishers, and Conflict of Interest. Jama. 2017;317(17):1759-1760. doi:10.1001/jama.2017.3421.
  50. Ahmed I, Sutton AJ, Riley RD. Assessment of publication bias, selection bias, and unavailable data in meta-analyses using individual participant data: a database survey. Bmj. 2012;344:d7762. doi:10.1136/bmj.d7762.